Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.

J Clin Oncol · 2023 · PMC10115555 · PMID 36473143

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The median OS was 13.9 months (95% CI, 12.1 to 15.8) with nivolumab plus ipilimumab versus 13.5 months (95% CI, 12.6 to 15.2) with EXTREME in the all randomly assigned population and 17.6 months (95% CI, 13.8 to 22.0) versus 14.6 months (95% CI, 12.3 to 16.0) in the CPS ≥ 20 population and did not reach statistical significance in either population.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.